VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

Key Takeaways Viking Therapeutics completed enrollment in the phase III VANQUISH-2 study of obesity drug VK2735.The trial targets ~1,000 T2D patients, testing weekly doses with weight loss over 78 weeks as the endpoint.Rapid enrollment and prior data showing up to 14.7% weight loss highlight strong interest in VK2735.Shares of Viking Therapeutics (VKTX) rose more than 3% on Thursday after the company announced that it completed enrollment in the phase III VANQUISH-2 study, which is evaluating the subcutaneo ...